2022

1. A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

   Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 93-100